Ketonuria is not associated with hyperemesis gravidarum disease severity.


Journal

European journal of obstetrics, gynecology, and reproductive biology
ISSN: 1872-7654
Titre abrégé: Eur J Obstet Gynecol Reprod Biol
Pays: Ireland
ID NLM: 0375672

Informations de publication

Date de publication:
Nov 2020
Historique:
received: 08 02 2020
revised: 30 07 2020
accepted: 21 08 2020
pubmed: 13 10 2020
medline: 15 5 2021
entrez: 12 10 2020
Statut: ppublish

Résumé

To assess the association between ketonuria and hyperemesis gravidarum (HG) disease severity. We included pregnant women hospitalised for HG who participated in the Maternal and Offspring outcomes after Treatment of HyperEmesis by Refeeding (MOTHER) trial and women who were eligible, chose not to be randomised and agreed to participate in the observational cohort. Between October 2013 and March 2016, in 19 hospitals in the Netherlands, women hospitalised for HG were approached for study participation. The presence of ketonuria was not required for study entry. Ketonuria was measured at hospital admission with a dipstick, which distinguishes 5 categories: negative and 1+ through 4 + . The outcome measures were multiple measures of HG disease severity at different time points: 1) At hospital admission (study entry): severity of nausea and vomiting, quality of life and weight change compared to pre-pregnancy weight, 2) One week after hospital admission: severity of nausea and vomiting, quality of life and weight change compared to admission, 3) Duration of index hospital admission and readmission for HG at any time point RESULTS: 215 women where included. Ketonuria was not associated with severity of nausea and vomiting, quality of life or weight loss at hospital admission, nor was the degree of ketonuria at admission associated with any of the outcomes 1 week after hospital admission. The degree of ketonuria was also not associated with the number of readmissions. However, women with a higher degree of ketonuria had a statistically significant longer duration of hospital stay (per 1+ ketonuria, difference: 0.27 days, 95 % CI: 0.05 to 0.48). There was no association between the degree of ketonuria at admission and severity of symptoms, quality of life, maternal weight loss, or number of readmissions, suggesting that ketonuria provides no information about disease severity or disease course. Despite this, women with a higher degree of ketonuria at admission were hospitalised for longer. This could suggest that health care professionals base length of hospital stay on the degree of ketonuria. Based on the lack of association between ketonuria and disease severity, we suggest it has no additional value in the clinical management of HG.

Identifiants

pubmed: 33045502
pii: S0301-2115(20)30526-1
doi: 10.1016/j.ejogrb.2020.08.014
pii:
doi:

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

315-320

Informations de copyright

Copyright © 2020. Published by Elsevier B.V.

Déclaration de conflit d'intérêts

Declaration of Competing Interest None declared. Completed disclosure of interests form available to view online as supporting information.

Auteurs

M H Koot (MH)

Department of Obstetrics and Gynecology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands; Department of Clinical Epidemiology, Biostatistics and Bioinformatics, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands. Electronic address: m.h.koot@amsterdamumc.nl.

I J Grooten (IJ)

Department of Obstetrics and Gynecology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands; Department of Obstetrics and Gynaecology, Noordwest Ziekenhuisgroep, Alkmaar, The Netherlands.

J A M Vd Post (JAMV)

Department of Obstetrics and Gynecology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.

J M J Bais (JMJ)

Department of Obstetrics and Gynaecology, Noordwest Ziekenhuisgroep, Alkmaar, The Netherlands.

C Ris-Stalpers (C)

Department of Obstetrics and Gynecology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands; Laboratory of Reproductive Biology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.

C A Naaktgeboren (CA)

Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, University Utrecht, The Netherlands.

M N Niemeijer (MN)

Department of Obstetrics and Gynaecology, HMC Westeinde, The Hague, The Netherlands.

H A Bremer (HA)

Department of Obstetrics and Gynecology, Reinier de Graaf Hospital, Delft, The Netherlands.

D P van der Ham (DP)

Department of Obstetrics and Gynecology, Martini Hospital, Groningen, The Netherlands.

W M Heidema (WM)

Department of Obstetrics and Gynecology, Radboud University Medical Center, Nijmegen, The Netherlands.

A Huisjes (A)

Department of Obstetrics and Gynecology, Gelre Hospital, Apeldoorn, The Netherlands.

G Kleiverda (G)

Department of Obstetrics and Gynecology, Flevo Hospital, Almere, The Netherlands.

S M Kuppens (SM)

Department of Obstetrics and Gynecology, Catharina Hospital, Eindhoven, The Netherlands.

J O E H van Laar (JOEH)

Department of Obstetrics and Gynecology, Máxima Medical Center, Veldhoven, The Netherlands.

J Langenveld (J)

Department of Obstetrics and Gynecology, Zuyderland Hospital, Heerlen, The Netherlands.

F van der Made (F)

Department of Obstetrics and Gynecology, Franciscus Gasthuis, Rotterdam, The Netherlands.

D Papatsonis (D)

Department of Obstetrics and Gynecology, Amphia Hospital, Breda, The Netherlands.

M J Pelinck (MJ)

Department of Obstetrics and Gynecology, Scheper Hospital, Emmen, The Netherlands.

P J Pernet (PJ)

Department of Obstetrics and Gynecology, Spaarne Gasthuis, Haarlem, The Netherlands.

L van Rheenen-Flach (L)

Department of Obstetrics and Gynecology, OLVG, Amsterdam, The Netherlands.

R J Rijnders (RJ)

Department of Obstetrics and Gynecology, Jeroen Bosch Hospital, 's-Hertogenbosch, The Netherlands.

H C J Scheepers (HCJ)

Department of Obstetrics and Gynecology, Maastricht University Medical Center, Maastricht, The Netherlands.

T E Vogelvang (TE)

Department of Obstetrics and Gynecology, Diakonessenhuis, Utrecht, The Netherlands.

B W Mol (BW)

Department of Obstetrics and Gynecology, Monash University, Clayton, Victoria, Australia.

T J Roseboom (TJ)

Department of Obstetrics and Gynecology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands; Department of Clinical Epidemiology, Biostatistics and Bioinformatics, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.

R C Painter (RC)

Department of Obstetrics and Gynecology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH